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AAG: α1-acid glycoprotein 
ABCB1: Adenosine triphosphate binding cassette member B1  
ABCC2: Adenosine triphosphate binding cassette member C2  
ABCG2: Adenosine triphosphate binding cassette member G2  
ACAT model: Advanced Compartmental Absorption and Transit model 
ADAM model: Advanced Dissolution, Absorption and Metabolism model 
ADME: Absorption, distribution, metabolism, excretion 
AUC: Area under the curve 
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BCRP: Breast cancer resistance protein 
CAT model: Compartmental Absorption and Transit model 
CYP: Cytochrome P450 
GFR: Glomerular filtration rate 
HPGL: Hepatocellularity 
IPA: Isopropanol 
MCMC: Markov Chain Monte Carlo 
MDR1: Multi-drug resistance protein 
MRP2: Multidrug-resistance protein 2 
PBPK: Physiologically Based Pharmacokinetic Model 
P-gp: P-glycoprotein 
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ABSTRACT 
Generic PBPK models, applicable to a large number of substances, coupled to parameter 
databases and QSAR modules, are now available for predictive modelling of inter-individual 
variability in the absorption, distribution, metabolism and excretion of environmental chemicals. 
When needed, Markov chain Monte Carlo methods and multilevel population models can be 
jointly used for a Bayesian calibration of a PBPK model, to improve our understanding of the 
determinants of population heterogeneity and differential susceptibility. This article reviews 




Drug-drug interactions, Markov chain Monte Carlo, Monte Carlo simulations, PBPK models, 
Pharmacokinetics, Population models, Susceptible populations, Toxic interactions, 
Toxicokinetics, Variably assessment. 
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1. INTRODUCTION 
PBPK models are now commonly used in drug development and regulatory toxicology to predict 
the kinetics and metabolism of substances in the body, with a focus on the effective dose at the 
expected target site (Barton et al. 2007; Bouvier d'Yvoire et al. 2007; Edginton et al. 2008; 
Loizou et al. 2008). 
The physiological basis of PBPK models makes them especially suited to explore, understand 
and predict the determinants of inter- or intra-individual variability in pharmacokinetics. Those 
translate into variability of target doses and can have direct consequences for therapeutic safety 
and the likelihood of toxicity, especially for compounds with narrow therapeutic windows or a 
steep dose-response for toxicity. Therefore, simulation of inter-individual variability has become 
an integral part of the assessment of pharmacokinetics in humans (Bois 2001; Rostami-Hodjegan 
and Tucker 2007). The mechanistic framework of PBPK models provides the capacity of 
predicting inter-individual variability in pharmacokinetics when the required information is 
adequately incorporated. This short review presents the state of the art on this question and 
illustrates the approach with two recent applications of the Simcyp software to environmentally 
relevant questions. 
2. PBPK MODELING 
When a chemical substance penetrates an animal body (following intentional administration or 
unintentional exposure), it is usually distributed to various tissues and organs by blood flow 
(Gerlowski and Jain 1983; Nestorov 2007). Following its distribution to tissues, the substance 
can bind to various proteins and receptors, undergo metabolism, or can be eliminated unchanged. 
The concentration versus time profiles of the xenobiotic in different tissues, or the amount of 
metabolites formed, are often used as surrogate markers of its internal dose or biological activity 
(Andersen 1995).  
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Mathematical models can be used to interpolate and extrapolate (predict) such concentration-
time profiles from data. Reported models range from simple compartmental (Gibaldi and Perrier 
1982) to very sophisticated (Jamei et al. 2009a; Luecke et al. 2008). PBPK models are evolved 
compartmental models which tend to use realistic biological descriptions of the determinants that 
regulate the disposition of drugs in the body (Andersen et al. 2005). Those models describe the 
body as a set of compartments corresponding to specific organs or tissues (e.g., adipose, bone, 
brain, gut, heart, kidney, liver, lung, muscle, skin, and spleen, etc.). Between compartments, the 
transport of substances is dictated by various physiological flows (blood, bile, pulmonary 
ventilation, etc.) or by diffusion (Bois and Paxman 1992; Gerlowski and Jain 1983). Perfusion-
rate-limited kinetics applies when the tissue membrane presents no barrier to distribution. 
Generally, this condition is likely to be met by small lipophilic substances. In contrast, 
permeability-rate kinetics applies when the distribution of the substance to a tissue is rate-limited 
by the drug’s permeability across the tissue membrane. That condition is more common with 
polar compounds and large molecular structures. Consequently, the related PBPK models may 
exhibit different degrees of complexity. In the simplest and most commonly applied form (see 
Figure 1), each tissue is considered to be a well-stirred compartment in which the substance 
distribution is simply limited by blood flow. In such a model, any of the tissues can be a site of 
elimination. However, in Figure 1, it is assumed that the gut, liver and kidney are the only 
metabolising tissues and that excretion only happens in the kidney.  
Building a PBPK model requires gathering a considerable amount of data which can be 
categorised in three groups: namely, the system’s data (physiological, anatomical, biochemical 
data); drug-specific data; and the model structure, which refers to the arrangement of tissues and 
organs included in the model (Rowland et al. 2004). In a sense, PBPK modelling is an integrated 
systems approach to both understanding the pharmacokinetic behaviour of compounds and 
predicting concentration-time profiles in plasma and tissues. Additional details on PBPK 
modelling can be found elsewhere (Gerlowski and Jain 1983; Nestorov 2003; Rowland et al. 
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2004). Indeed, such a description of the body is approximate, if not rough, but a balance has to 
be found between precision (which implies complexity) and simplicity (for ease of use). Yet, the 
generic structure of a PBPK facilitates its application to any mammalian species as long as the 
related system data are used. Therefore, the same structural model can approximately be used for 
a human, a rat or a mouse.  
The model structure can be described by a set of differential equations, with parameters repre-
senting blood flow rates, organ volumes etc., for which information is available in the published 
scientific literature or may be obtained in vitro (Parrott et al. 2005; Woodruff and Bois 1993). 
Numerical integration of that differential system computes the quantity and concentration of the 
drug considered in each compartment, as a function of time and exposure dose.  
3. VARIABILITY VS. UNCERTAINTY 
Inter-individual differences (“variability”), in the anatomical and physiological characteristics of 
humans or animal are glaring and a common experience. Such differences affect, for example, 
organ volumes and blood flow and translate quite naturally into variability in the 
pharmacokinetics of drugs and chemical substances from one individual to the next. Since 
pharmacokinetics determine, in part, effective dose and ensuing effects, pharmacokinetic 
variability has an impact on individual susceptibility. Two major, complementary, modelling 
approaches have been developed to understand, evaluate and predict that variability: A priori and 
a posteriori modelling. 
A priori (bottom-up), purely predictive, modelling of variability can be undertaken either 
through deterministic descriptions of the determinants of variability or through stochastic 
simulations (Monte Carlo methods) (Bois et al. 1990; Clewell and Andersen 1996; Clewell et al. 
2004; Rostami-Hodjegan and Tucker 2007; Willmann et al. 2009; Willmann et al. 2007). Both 
approaches can also be combined. Deterministic modelling motivations stem, partly, from the 
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fact that some of the differences between individuals are due to growth and other age-related 
changes, or sex, etc. Such changes can be explicitly modelled in life-time PBPK models (Clewell 
et al. 2004; Edginton et al. 2006). Monte Carlo methods acknowledge (some may say: hide 
intellectual laziness behind) the fact that part of the differences between individuals seem to 
occur by chance or cannot be ascribed simply to easily modelled determinants such as age etc. In 
that case, those differences are considered as purely random and parameter values are described 
by statistical distributions, rather than point estimates or simple functions of time, sex or other 
covariates. 
A posteriori (top-down) modelling of inter-individual variability is data-based, and was 
originally developed in pharmacokinetics, where human data were routinely generated through 
clinical trials. The aim here is to assess, for example, how across-subject variability of blood 
concentration for a substance can be explained by variability in renal excretion rate, 
bioavailability, metabolic rate, etc. That is best achieved through inverse simulation in the 
framework of multilevel statistical models (“population pharmacokinetic models”) (Bois 2001; 
Sheiner 1984). That approach was first used with classical (minimal) compartmental models 
(Beal and Sheiner 1980, 1982), but the added ingredients of MCMC simulations and Bayesian 
inference make it amenable to the treatment of PBPK models (Bois et al. 1996a; Bois et al. 
1996b; Gelman et al. 1996). After unrolling the determinants of variability, forward, predictive, 
simulations can be performed to assess their impact in various exposure and risk or clinical 
treatment scenarios. 
Uncertainty is different from variability, although their effects may be confounded and 
compounded. Uncertainty is essentially due to lack of knowledge and may have various sources. 
For example, measurements are made only with finite precision; so when data are used to fit 
toxicokinetic or toxicodynamic models, there is always some uncertainty ("noise") about the 
estimated parameters values. Also, studying a limited population sample introduces an element 
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of randomness when attempting to extrapolate the results to the whole population. Finally, our 
inability to describe or model precisely a system may result from our lack of understanding and 
simplifications or misspecifications of the fitted models translate into parametric uncertainty 
(Bois 2001; Bois and Diack 2005). While variability is by essence irreducible and unavoidable, 
since it is a state of Nature, uncertainty can be reduced by new experiments, or by a better 
understanding of the biology and better models. In a further twist, the fact that uncertainty is 
almost always present hampers a precise assessment of variability. Statistical "population" 
models are able to disentangle partly uncertainty from variability. These models will be reviewed 
in section 7, below. 
4. A PRIORI PREDICTION OF VARIABILITY USING PBPK MODELING 
Predictive variability assessment with PBPK models proceeds nowadays with a combination of 
mechanism and data based refinements of the model structure (e.g., using age-dependent 
compartment volumes) (Clewell et al. 2004; Luecke et al. 2008) and stochastic modelling of the 
remaining random components of inter-individual differences. Numerical Monte Carlo methods 
(Clewell et al. 1999; Price et al. 2003; Spear et al. 1991; Woodruff et al. 1992), eventually 
hierarchical (Bois 1999; Bois et al. 1996a; Bois et al. 1996b), are the most widely used for the 
latter task. Those are best suited for complex models with many parameters. The basic 
assumption made by Monte Carlo simulations is that the randomness of the model state variables 
(e.g., blood concentration) is simply due to the randomness in the model parameter values. It is 
then enough to define statistical distributions for the parameters supposed to vary randomly in 
the population, and to sample the model parameter values from those distributions. The model is 
then run with the needed inputs and its outputs of interest are recorded. That sampling-running 
step constitutes a basic Monte Carlo iteration. As many iterations as needed can be performed to 
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characterise precisely the statistical distribution of the recorded outputs. Additional details on 
Monte Carlo methods can be found in Ripley (1987). 
Early attempts to use Monte Carlo methods and to simulate pharmacokinetic behaviour in 
“virtual populations” date back to the mid-1980s. Jackson et al. assessed the robustness of dif-
ferent experimental in vivo indices to detect and display genetic polymorphisms in human drug-
metabolising activity (Jackson and Tucker 1990; Jackson et al. 1986). Monte Carlo analyses of 
PBPK models were also described at that time (Bois et al. 1990; Portier and Kaplan 1989). These 
simulations were later expanded to show the effect of variability in absorption, distribution, 
metabolism and excretion (ADME) parameters on the power of single time point estimates for 
the assessment of metabolic activity (Jackson et al. 1991), power analyses of bioequivalence 
measures (Bois et al. 1994a, b), the differentiation of parent drug and metabolite data in 
bioequivalence assessment (Rostami-Hodjegan et al. 1994), the discriminatory power of 
different indices of in vivo enzyme activity and the optimisation of sampling to assess such 
activity (Rostami-Hodjegan et al. 1996). Coupled with Monte Carlo methods, PBPK modelling 
has been used to assess the quantitative impact of physiological and environmental factors on 
human variability in toxicokinetics and pharmacokinetics in other publications (Bois et al. 1991; 
Clewell and Andersen 1996; Jamei et al. 2009a; Nestorov 2001; Sato 1991).  
5. SOURCES OF VARIABILITY IN PHARMACOKINETICS 
The overall inter-individual variability in pharmacokinetics can be simulated by considering the 
variability in key system parameters in PBPK modelling (Jamei et al. 2009a) (see Figure 2 for 
examples of clearance covariates). Details on the prediction of inter-individual variability in 
pharmacokinetics are discussed in detail below.  
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5.1. ABSORPTION 
There are many routes for xenobiotics to enter into the body which can generally be divided into 
topical, enteral and parenteral categories. Some of these routes (oral, infusion, intravenous, 
intramuscular, transdermal and inhalation) are routinely used to administrate drugs. The oral, 
transdermal and inhalation routes, which are most relevant to environmental exposures, are 
briefly discussed in this section.  
Oral administration is the most common and convenient route of drug administration. Yet, it is 
often associated with low bioavailability and high inter-individual variability. Oral 
bioavailability (Foral) is defined as: 
 HGaoral FFfF  (1) 
where fa is the net fraction of dose absorbed from the intestinal tract, FG is the fraction of dose 
that escapes intestinal first-pass metabolism in the enterocytes, and FH is the fraction of dose that 
escapes hepatic first-pass metabolism. fa is discussed in this section and FG and FH will be 
discussed later. 
Various factors can affect oral drug absorption. They can be divided into two categories: system 
(physiological and biological) factors and drug-related (physicochemical and pharmaceutical) 
factors. These factors can all contribute to the overall rate and extent of absorption, but mainly 
the system factors determine the inter-individual variability in absorption.  
5.1.1. Oral Absorption 
Key physiochemical properties, such as solubility and permeability are used in empirical 
methods to estimate the absorption potential of a drug (Artursson and Karlsson 1991; Dressman 
et al. 1985). Physiological models, such as the CAT model, have been developed to simulate 
mechanistically drug absorption (Yu and Amidon 1999). The CAT model has been further 
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developed into the ACAT (Agoram et al. 2001) and the ADAM (Jamei et al. 2009b) models, 
which are respectively implemented within software Gastroplus (Simulation Plus Inc, California, 
USA, http://www.simulationsplus.com) and Simcyp Population-based ADME Simulator 
(Simcyp Ltd, Sheffield, UK, http://www.simcyp.com). In brief, these absorption models consist 
of physiologically based compartments corresponding to different segments of the gastrointes-
tinal tract.  
Gastric Emptying Time 
The residence time of a drug in the stomach is an important factor determining the initiation of 
oral drug absorption. Variability in gastric emptying rates results in variable absorption rates and 
sometimes even variable absorption extents.  
Intestinal Residence Time  
Intestinal residence time can greatly affect oral drug absorption; particularly for drugs with low 
permeability. Yu and co-workers analyzed published data for low intestinal residence time in 
over 400 subjects and reported a mean value of 199 min with ranges of about 1 and 6 hours (Yu 
et al. 1996). Intestinal residence time appears to be relatively less dependent upon the nature of 
the dosage form (liquid vs. solid) than gastric residence time (Davis et al. 1986). The presence of 
food appears not to influence intestinal transit (Davis et al. 1986; Fadda et al. 2009). 
Gastrointestinal pH 
The regional pH in the gastrointestinal tract can influence drug solubility and hence the 
dissolution of solid dosage forms. Gastrointestinal pH may also affect drug permeability by 
influencing the balance between ionised and non-ionised moieties. Fallingborg and co-workers 
measured pH profiles along the gastrointestinal tract in 39 healthy volunteers and observed a 
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range of values up to two pH units at the same site in different subjects (Fallingborg et al. 1989). 
In addition, the presence of food in the gastrointestinal tract can raise the pH in the stomach and 
the proximal part of the small intestine, due to the buffering capacity of proteins.  
Transporters 
Various transporters are expressed in the apical and basolateral membranes of intestinal 
epithelial cells (Hilgendorf et al. 2007; Koepsell 1998; Koepsell et al. 2007; Murakami and 
Takano 2008; Tsuji and Tamai 1996). Much attention has been given to the efflux transporters 
(e.g., P-gp, MDR1 (ABCB1), MRP2 (ABCC2) and BCRP (ABCG2)) at the apical (brush-
border) membrane of the intestine, as they can limit the intestinal absorption of drugs 
administered orally. Von Richter et al. (2004) measured P-gp in the human small intestine and 
reported a marked inter-individual variation in the intestinal P-gp expression. Additional data 
were reported by several later publications (Canaparo et al. 2007; Mouly and Paine 2003). 
Available data demonstrate that the expression levels of transporters vary along the 
gastrointestinal tract. Mouly and Paine (2003) found that relative P-gp levels increase 
progressively from the proximal to distal region of the small intestine. Other intestinal 
transporters may or may not follow the same pattern. 
5.1.2. Inhalation 
The large absorptive surface area, limited metabolic enzyme activity and active transporters in 
the pulmonary system make inhalation a favourable delivery strategy for systemic drugs with 
low bioavailability. In addition, many chemicals present in the air can get into body via the 
respiratory system. As for other routes of administration, the absorption kinetics in the lung 
tissues depend on both drug and system related parameters. Although inhalation is an established 
delivery strategy, the relationship between drug physicochemical properties and drug absorption 
kinetics in the lung has not been extensively investigated. In contrast to oral drug absorption 
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little attention has been devoted to the question of how to optimize local drug absorption and 
retention in the lung (Yu and Rosania 2010). The state of the art on this question is somewhat 
more advanced for occupational exposures to volatile substances (Johanson 1990; Löf and 
Johanson 1998). Different aspects of lung physiology and formulation composition that 
influence the systemic delivery of inhaled therapeutics and recent advancement in inhaled drug 
delivery are reviewed in Patton and Byron (2007). 
5.1.2. Dermal Absorption 
The skin, the largest interface between the body and the environment, protects our body against 
chemical, physical, and microbial injury, loss of water, and other endogenous substances. It is 
also involved in the thermoregulation of the body and serves as an excretory organ (Schaefer et 
al. 2008). Understanding skin absorption processes enables us to assess the safety aspects of 
chemicals, xenobiotics, and cosmetic formulations as well as optimally utilizing dermal drug 
delivery. Permeation of drug molecules across the skin occurs by passive diffusion according to 
the activity gradient (Cleek and Bunge 1993; Krüse et al. 2007; McCarley and Bunge 2001; Potts 
and Guy 1992). The outer skin layer, stratum corneum, forms a rate-controlling barrier for 
diffusion of most compounds. The predominant diffusional path for a molecule crossing the 
stratum corneum appears to be intercellular (Hadgraft and Guty 2002). However this path is not 
exclusive and probably most molecules will pass through the stratum corneum by a combination 
of intercellular lipid domains, transcellular route and via the appendages (hair follicles, etc.) 
(Farahmand and Maibach 2009b). 
Farahmand et al. investigated dermato-pharmacokinetic parameters of 12 transdermal patches 
and concluded that the serum concentration profile for transdermal therapeutic systems was 
affected by the physiological parameters, drug absorption and elimination. Therefore, in order to 
understand the variability in serum concentration it is necessary to take into account variability 
of each process involved (Farahmand and Maibach 2009a).  
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5.2 DISTRIBUTION 
The distribution process refers to the reversible transfer of drug from one location to another 
within the body. Factors that determine the distribution pattern of a drug with time include 
delivery of drug to tissue by blood, ability to cross tissue membranes, binding within blood and 
tissues, partitioning into fat, and tissue uptake (Rowland and Tozer 1995). The traditional 
description of the volume of distribution at steady state (Vss) corresponds to the sum of the 
products of each tissue to plasma partition coefficient (Kp:t) and the respective tissue volume in 
addition to the plasma volume (Sawada et al. 1984): 
 
tptepss KVPEVVV :):(  (2) 
where Vp, Ve and Vt are the volumes of plasma, erythrocyte and tissue, respectively, E:P is 
erythrocyte-to-plasma coefficient. Physiological factors affecting drug distribution include tissue 
volumes, tissue composition, blood perfusion rates to the tissues, plasma protein concentrations, 
hematocrit, and the expression of transporter proteins. Drug-specific factors determining the 
distribution behaviour of a drug include its ionisation, ability to cross membranes, bind to plasma 
proteins, partition into red blood cells and fat, and its specific affinity to influx or efflux 
transporter proteins.  
Direct determination of Kp:t usually involves intravenous constant infusions to animals followed 
by an extraction and quantification of drugs from tissue homogenates (Lin et al. 1982a, b; 
Sawada et al. 1984), which is costly and time consuming. It is, therefore, of interest to predict 
Kp:t values without conducting in vivo animal studies.  
Several mechanistic equations have been proposed to predict the tissue affinities of volatile 
organic compounds (Fiserova-Bergerova 1983; Fiserova-Bergerova and Diaz 1986; Fiserova-
Bergerova et al. 1980). Poulin and co-workers also developed mechanistic equations to predict 
the affinity of drugs for various tissues and organs (Poulin et al. 2001; Poulin and Theil 2000) 
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and subsequently Vss predictions (Poulin and Theil 2002a) using Eq. 2. The species-specific 
tissue composition parameters can be found in the literature and have been summarised by 
Poulin and Theil (2002b). Corrections on these equations were later made by Berezhkovskiy 
(2004). More recently, Rodgers and co-workers extended and improved these equations by 
considering drug ionisation and incorporating more details on drug distribution inside tissues 
(Rodgers et al. 2005; Rodgers and Rowland 2006). Briefly, those equations are based on the 
assumption that all drugs will dissolve in intra- and extracellular tissue water and partition into 
the neutral lipids and neutral phospholipids located within tissue cells. 
5.2.1 Tissue Volumes and Tissue Blood Flows 
Tissue volumes and blood flows are essential components of a PBPK model. Early publications 
reported representative physiological parameters values but did not indicate the biological 
variability associated with those data (Davies and Morris 1993; Williams and Leggett 1989). 
Inter-individual variability on tissue volumes and tissue blood flows has been reported by later 
publications (de la Grandmaison et al. 2001; Price et al. 2003).  
5.2.2 Tissue Composition 
Hematocrit refers to the percentage of total blood volume composed of red blood cells. It is 
influenced by factors including age, sex, seasonal influence, and habits of physical activity 
(Morse et al. 1947a; Morse et al. 1947b; Thirup 2003). Compared with men, women on average 
have lower hematocrit. Hematocrit ranges between 40%–54% in males and 38%–47% in 
females. 
Drug protein binding is the reversible interaction of drugs with plasma proteins. The extent of 
protein binding is a function of drug and protein concentrations, the affinity constant for the 
drug-protein binding and the number of protein binding sites (Grandison and Boudinot 2000). 
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The major drug binding proteins in plasma are: albumin, AAG and lipoproteins. Albumin levels 
are generally decreased with age, whereas AAG levels are not significantly affected by age.  
5.2.3 Transporters 
Numerous drug transporters are found on the membranes of various tissues. These transporters 
can influence drug distribution into the tissues, particularly for drugs with low passive 
permeability. There is now increasing evidence to suggest that transporters may affect the 
volumes of distribution of certain drugs (Grover and Benet 2009). For most drugs, however, 
transporters may not significantly influence the volume of distribution, but may still influence 
the local kinetics in certain tissues (e.g., brain, liver, etc) and cause pharmacological or 
toxicological consequences. Polymorphism has been identified in transporters, as reviewed by 
Ho and Kim (2005).  
5.3 METABOLISM 
Drug metabolism reactions are generally grouped into 2 phases. Phase I metabolism includes 
oxidation, reduction, hydrolysis and hydration reactions. Phase II reactions use an endogenous 
compound, such as glucuronic acid, glutathione, or sulphate, for conjugation to the drug or its 
phase I-derived metabolite to produce a more polar end product that can be more readily 
excreted in bile or urine.  
Although drug metabolism can take place in many organs, the liver has been long-recognised as 
the major site of metabolism for most drugs. More recently, the role of gut metabolism in first-
pass metabolism has been increasingly recognised. The intestinal tissue is endowed with phase I 
and II enzymes, although at lower levels than those for the liver (Pang 2003). Several CYP 
enzymes have been detected in the human small intestine, including CYP1A2, CYP2D6, 
CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 (Paine et al. 2006). Among 
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them, CYP3A4 is the most prominent enzyme present in the human intestine (Paine et al. 2006; 
Paine et al. 1997).  
5.3.1 Hepatic Metabolism 
Rane et al. (1977) successfully predicted in vivo hepatic metabolic clearance in rats based on in 
vitro data obtained from rat liver microsomes, taking into consideration the hepatic blood flow 
rate and the unbound fraction in blood. Since then, significant progresses have been achieved on 
predicting human hepatic metabolic clearance from a variety of in vitro systems, such as human 
liver microsomes, recombinant enzymes, and hepatocytes (Galetin et al. 2004; Houston 1994; 
Howgate et al. 2006; Iwatsubo et al. 1997; Obach 1999; Riley et al. 2005). 
The unbound total hepatic intrinsic clearance (CLuint,H) can be extrapolated from in vitro 
clearance determined in a variety of in vitro systems using scaling factors as described in Barter 
(2007) and according to the procedure described by Rostami-Hodjegan and Tucker (2007): 
















where there are i metabolic pathways for each of j enzymes; ‘rh’ indicates recombinantly 
expressed enzyme; Vmax is the maximum rate of metabolism by an individual enzyme; Km is 
the Michaelis constant; MPPGL is the amount of microsomal protein per gram of liver; and ISEF 
is a scaling factor that compensates for any difference in the activity per unit of enzyme between 
recombinant systems and hepatic enzymes (Proctor et al. 2004). 
Human liver microsomes: 
 weightLiverMPPGLmicrosomesmgper _)__(CLuCLu intHint,  (4) 
Human hepatocytes: 
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 weightLiverHPGLshepatocytemillionsper _)__(CLuCLu intHint,  (5) 
where HPGL refers to hepatocellularity (millions of hepatocytes per gram of liver). 
CLuint,H is then combined with other determinants to obtain total hepatic intrinsic clearance, 
using a liver model. Several hepatic clearance models have been developed to quantify the 
effects of hepatic blood flow, fraction unbound in blood, and hepatic intrinsic clearance on 
hepatic clearance (Wilkinson 1987). Among these models the well-stirred model (Eqs. 6 and 7) 


















where CLH,B is hepatic drug clearance based on whole blood drug concentration, QH,B is hepatic 
blood flow, fuB is the free fraction of drug in blood.  
As indicated by Eq. 6, inter-individual variability in CLH,B is influenced by the variability in 
three key parameters: QH,B,  fuB and CLuint,H.  
5.3.2 Gut Metabolism 
An operational model has been developed to predict first-pass metabolism in the gut. The “QGut” 
model (Eq. 8) (Rostami-Hodjegan and Tucker 2002; Yang et al. 2007; Yang et al. 2001) retains 
the form of the “well-stirred” model but the flow term (QGut) is a hybrid of both permeability 









where FG is intestinal availability (fraction of dose that escapes intestinal first-pass metabolism 
in the enterocytes), fuG is the fraction of drug unbound in the enterocyte and its value is close to 
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1 in most cases (Yang et al. 2007), CLuint,G is the unbound total gut intrinsic clearance, and QGut 





CLQQ  (9) 
where CLperm is a clearance term defining permeability through the enterocyte and Qvilli is villous 
blood flow (Yang et al. 2007).  
5.4 EXCRETION 
Excretion is the irreversible loss of the chemically unchanged drug. For most drugs, excretion 
occurs predominantly via the kidneys. However, some drugs and their metabolites are 
extensively excreted via the bile. Drug excretion can also happen via saliva, sweat, breast milk, 
and lungs, although their contributions to overall drug elimination are often small. 
5.4.1. Renal Excretion 
The kidney is the major site of drug excretion. Net renal drug excretion is a combination of three 
processes – glomerular filtration, tubular secretion and tubular reabsorption, as described by Eq. 
10. Glomerular filtration of a drug is a passive process that is dependent upon the unbound 
fraction of a drug in plasma (fu) and renal blood flow available for filtration, as described by Eq. 
11. Tubular secretion occurs predominantly in the proximal tubule, and is mediated by several 
families of transporters. Tubular reabsorption of a drug can be a passive or an active transport 
process. Passive reabsorption may occur throughout the nephron. Active reabsorption occurs in 
the proximal tubule and, similar to tubular secretion, is energy-dependent, saturable, 
stereospecific and also likely to be associated with competitive drug interactions (Tett et al. 
2003). 
 Rate of Excretion = (Rate of Filtration + Rate of Active Secretion)(1 – FR) (10) 
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 Rate of Filtration = fu × GFR × C (11) 
where FR is the fraction of drug reabsorbed from tubule lumen; fu is the fraction unbound in 
plasma; GFR is the glomerular filtration rate; and C is drug concentration in plasma.  
The primary determinants of renal excretion include renal blood flow, plasma protein binding, 
urine flow, urine pH, and renal transporters (Garrett 1978; Tucker 1981).  
Renal transporters play key roles in the secretion and reabsorption of many drugs and can 
significantly contribute to the variability in renal excretion of these compounds (Lee and Kim 
2004). Organic anion and organic cation transport systems are two major drug transport systems 
in the human kidney (Dresser et al. 2001), and the effects of genetic variations in transporters on 
renal clearance have been investigated recently (Wang et al. 2008). 
5.4.2 Biliary Excretion 
Biliary excretion is one of the primary elimination routes for xenobiotics and the conjugate 
metabolites (Arias et al. 1993). Biliary excretion requires active secretory transport because 
drugs are transported across the biliary epithelium against a concentration gradient. Often drugs 
excreted into the bile undergo some degree of reabsorption along the intestine (enterohepatic 
circulation).  
Ghibellini and co-workers used in vitro data obtained from sandwich-cultured human 
hepatocytes to predict the biliary clearance for three drugs, and the predicted values were 
significantly lower than in vivo data (Ghibellini et al. 2007). Biliary excretion is mediated by 
transporters in the canalicular membrane. Therefore, genetic variation in these transporters 
contributes to the inter-individual variability in biliary excretion. Several recent reviews have 
summarised the key transporters involved in hepatobiliary disposition of drugs (Chandra and 
Brouwer 2004; Ghibellini et al. 2006). 
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5.5 CO-EXPOSURES 
Part of the variability in metabolism observed in humans may also be due to uncontrolled co-
exposures to naturally occurring food-borne substances, environmental contaminants, therapeutic 
drugs, or chemical substances in the workplace. Drug-drug interactions are a well-known 
problem falling under that umbrella (Jamei et al. 2009a; Rostami-Hodjegan and Tucker 2007), 
but its generalisation to many-substance exposure remains to be better explored. The necessary 
tools are becoming available under the auspices of systems biology (Bois 2010). 
6. EXAMPLES OF APPLICATION OF A PRIORI MODELLING TO 
CHEMICAL RISK ASSESSMENT 
Risk assessments are performed to estimate the conditions under which individuals or 
populations may be harmed by exposure to environmental or occupational chemicals. In the 
absence of quantitative data in the human, this process is often dependent upon the use of animal 
and in vitro data to estimate human response. To reduce the uncertainty inherent in such 
extrapolations, there has been considerable interest in the development of PBPK models of toxic 
chemicals for application in quantitative risk assessments. PBPK models are effective tools for 
integrating internal dose assessment with diverse dose-response and mechanistic data in order to 
more accurately predict human risk (Andersen et al. 1987). One of the more challenging issues 
that must be considered in performing a human health risk assessment is the heterogeneity 
among humans. This heterogeneity is produced by inter-individual variations in physiology, 
biochemistry, and molecular biology, reflecting both genetic and environmental factors, and 
results in differences among individuals in the biologically effective tissue dose associated with 
a given environmental exposure (pharmacokinetics) as well as in the response to a given tissue 
dose (pharmacodynamics).  
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There has sometimes been a tendency in risk assessments to use information on the variability of 
a specific parameter, such as inhalation rate or the in vitro activity of a particular enzyme, as the 
basis for expectations regarding the variability in dosimetry for in vivo exposures. However, 
whether or not the variation in a particular physiological or biochemical parameter will have a 
significant impact on in vivo dosimetry is a complex function of interacting factors. In particular, 
the structures of physiological and biochemical systems frequently involve parallel processes 
(e.g., blood flows, metabolic pathways, excretion processes), leading to compensation for the 
variation in a single factor. Moreover, physiological constraints may limit the in vivo impact of 
variability observed in vitro (Johanson et al. 1999). For instance, high affinity intrinsic clearance 
can result in essentially complete metabolism of all the chemical reaching the liver in the blood; 
under these conditions, variability in amount metabolized in vivo would be more a function of 
variability in liver blood flow than variability in metabolism in vitro. Thus it is often true that the 
whole (the in vivo variability in dosimetry) is less than the sum of its part (the variability in each 
of the pharmacokinetic factors). Because the parameters in a PBPK model have a direct 
biological correspondence, they provide a useful framework for determining the impact of 
observed variations in physiological and biochemical factors on the population variability in 
dosimetry within the context of a risk assessment for a particular chemical (Clewell and 
Andersen 1996; Price et al. 2003).  
 It is important at this point to remember the distinction made above between uncertainty and 
variability. Early attempts to distinguish the contributions of uncertainty and variability can be 
found in Bogen and Spear (1987) or Allen et al. (1996). Several studies have attempted to 
estimate the impact of parameter variability in PBPK models on risk assessment predictions 
using the Monte Carlo approach (Allen et al. 1996; Clewell and Andersen 1996; Clewell et al. 
1999; Clewell and Jarnot 1994). As will be discussed in the next section, the use of a hierarchical 
Bayesian approach and Markov chain Monte Carlo simulations makes it possible to refine prior 
estimates of parameter variability on the basis of experimental data. The hierarchical Bayesian 
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approach is increasingly being used to characterize both the uncertainty and variability in PBPK 
model predictions (Bois 2000; Gelman et al. 1996; Hack et al. 2006; Jonsson et al. 2001b; 
Jonsson and Johanson 2001a; Qiu et al. 2010).  
It is useful in that context to consider the total variability among humans in terms of three 
contributing sources: (1) the variation across a population of “normal” individuals at the same 
age, e.g., young adults; (2) the variation across the population resulting from their different ages, 
e.g., infants or the elderly; and (3) the variation resulting from the existence of subpopulations 
that differ in some way from the “normal” population, e.g., due to genetic polymorphisms. A 
fourth source of variability, health status, should also be considered, although it is frequently 
disregarded in environmental risk assessment. To the extent that the variation in physiological 
and biochemical parameters across these population dimensions can be elucidated, PBPK models 
can be used together with Monte Carlo methods to integrate their effects on the in vivo kinetics 
of a chemical exposure and predict the resulting impact on the distribution of risks (as 
represented by target tissue doses) across the population. The following examples illustrate the 
application of PBPK models to inform population variability of the three types described above. 
Example 1: Population Variability 
Acceptable exposures to environmental contaminants are typically defined using a single value, 
such as the USEPA’s Reference Dose (RfD), which represents a daily ingestion rate considered 
to be without harm for most individuals. In the case of methylmercury, a PBPK model was used 
in a Monte Carlo analysis to provide information on the distribution of acceptable ingestion rates 
across the population (Clewell et al. 2000; Clewell et al. 1999). That is in contrast to the 
regulatory approach based on a single point estimate obtained using conservative assumptions. 
In that analysis, the maternal hair concentration associated with neurological effects in the 
offspring from an epidemiological study was converted to an expected distribution of daily 
ingestion rates across a population of U.S. women of childbearing age. The resulting distribution 
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of acceptable daily ingestion rates (RfDs) ranged from approximately 0.3 to 1.1 μg/kg/day, with 
a population median (50th percentile) of 0.5 μg/kg/day. This population distribution was used to 
inform risk-benefit analysis for alternative risk management options for contaminated sediment. 
In essence, the question here was: “How conservative are default conservative assumptions?”. 
The answer, given by Monte Carlo derived uncertainty and variability estimates, was in that 
case: “Very conservative”. 
Example 2: Age-Dependent Variability 
The following example illustrates the use of PBPK modelling to investigate the impact of 
pharmacokinetic variability on risk for the case of age-dependent pharmacokinetics. Specifically, 
the question being evaluated in this example is how normal changes in pharmacokinetic 
parameters from birth, through childhood, and across adulthood affect the dosimetry for 
environmental exposures to chemicals. To this end, a previously developed PBPK model for 
isopropanol and its metabolite acetone (Clewell et al. 2001) was adapted to simulate the 
physiological and biochemical changes in humans associated with growth and aging. In the age-
dependent model, all physiological and biochemical parameters change with time based on data 
from the literature (Clewell et al. 2004).  
Figure 3 shows the results of using this age-dependent model to simulate continuous inhalation 
of isopropanol at 1 ppb, beginning at birth and continuing for 75 years (Clewell et al. 2004). The 
model predicts that, for the same inhaled concentration, the blood concentrations achieved 
during early life are significantly higher than those achieved during adulthood. In the case of the 
metabolite acetone, however, it should be noted that production from isopropanol metabolism 
would be only a small fraction of endogenous production from ketogenesis. Obviously, these are 
only model predictions, but while waiting for a real-life epidemiological validation (which 
would be very costly and difficult to perform), they form a reasonable and transparent basis for 
immediate decision making. 
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Example 3: Genetic Polymorphism 
The next example demonstrates the use of PBPK modelling, together with Monte Carlo 
techniques, to evaluate the impact of a genetic polymorphism for metabolism. In the example 
described here, the polymorphism of interest is for the enzyme paraoxonase. The PBPK model 
used in the analysis (Gearhart et al. 1993) describes exposure to parathion, its metabolism to 
paraoxon, and the inhibition of acetylcholinesterase by paraoxon. Paraoxonase is one of the 
enzymes responsible for the metabolic clearance of paraoxon. In vitro data on the two human 
alleles of paraoxonase (low and high activity) were used to develop distributions for the 
metabolism parameters in the PBPK model (Gentry et al. 2002). Monte Carlo simulations were 
then performed to generate the resulting distribution of predicted blood concentrations of 
paraoxon across a population, considering the variability in other pharmacokinetic parameters. 
Figure 4 displays the predicted distribution for the time-integrated (area under the curve) blood 
concentrations of paraoxon (mg-hr/L) across the sensitive population (dark bars), as compared to 
the “normal” population, following exposure to parathion at a dose of 0.033 mg/kg (Gentry et al. 
2002). The impact of genetic polymorphism is strongly dampened by rate-limiting 
pharmacokinetic effects, similarly to what was observed for methyl chloride (Johanson et al. 
1999). The calculation performed here lead to internal dose levels very different from those 
which would be obtained using naive “all or nothing” guessed estimates based solely on 
qualitative genotype considerations. 
7. A POSTERIORI ESTIMATION OF VARIABILITY USING BAYESIAN 
PBPK MODELING 
Purely predictive modelling, as described above, can be cross-validated by confronting its 
predictions (e.g., for plasma concentration of a substance) to data obtained of a sample of 
individuals. In the ideal case, data and predictions agree on average and in terms of variability 
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and no further model refinement is attempted. Yet, quite often, the predictions are less than 
“perfect” and may even be really poor (but publication bias reduces the visibility of that case). 
That may be the occasion to improve the model through some calibration or data integration 
procedure and learn something about the true determinants of variability in a population 
(Wakefield and Bennett 1996). However, some care should be taken to properly disentangle 
uncertainty from variability in that calibration process, while retaining the prior physiological 
knowledge afforded by PBPK modelling (Gelman et al. 1996). The "naive" approach consists in 
fitting individual subjects’ data separately, collecting the resulting individual parameter 
estimates and forming their average etc. That approach does not work and is actually incorrect if 
very precise parameter estimates cannot be obtained from the data (Beal and Sheiner 1982; 
Smith and Wakefield 1994). For ethical, feasibility or cost reasons, the data on individuals tend 
to be sparse in clinical pharmacokinetics or toxicokinetics. Such data usually lead to fairly 
uncertain parameter estimates and the so-called population approaches should then be used (Beal 
and Sheiner 1980).  
Population models, or multilevel models, were first introduced in the context of pharmacokinetic 
studies for drug development and evaluation (Sheiner 1984). Their objective is to obtain, from 
data on individuals, a quantitative description of the variability of the kinetics of a compound 
within a large population. The same structural (e.g., PBPK) model is used describe the data for 
each subject, and that the model parameters differ randomly between subjects (see Figure 5) 
(Bois et al. 1996a; Bois et al. 1996b). Such randomness characterises variability can be described 
by a multivariate probability distribution. In population models, information of each subject is 
reinforced by "borrowing strength" from the other subjects' data and the overall estimation 
process is improved. Individuals' metabolic clearance, for example, can be assumed to be log-
normally distributed around a "population mean", with a "population variance" which measures 
variability in the population. The population means and variances (one for each kinetic 
parameter supposed to vary between subjects) are aptly named "population" parameters. They 
 27 / 52 
are estimated during the model calibration (data fitting) together with the parameters of each 
subject (Bois 2001). 
A number of methods are available to calibrate population models  (Beal and Sheiner 1982; 
Davidian and Gallant 1992; Mallet et al. 1988; Racine-Poon and Smith 1990). Bayesian 
approaches have emerged as the best suited for PBPK models, given the large amount of prior 
information they require (Bernillon and Bois 2000; Gelman et al. 1996). But as we have seen 
above, a large amount of that information is already encoded as prior distributions, and updating 
those distributions with system’s level data, is simply a matter of using Bayesian numerical 
methods such as Markov chain Monte Carlo simulations (Gelman and Rubin 1996). 
A number of applications of posterior Bayesian PBPK modelling have been published: on 
benzene (Bois et al. 1996b), butadiene (Mezzetti et al. 2003), carbaryl (Nong et al. 2008), 
chloroform (Lyons et al. 2008), dichloromethane (Bois 1999; David et al. 2006; Johanson et al. 
1999; Jonsson et al. 2001b; Jonsson and Johanson 2001a, 2003; Marino et al. 2006; Marino and 
Starr 2007), methyl chloride (Jonsson et al. 2001a), methyl mercury (Allen et al. 2007), 
nanoparticles (Péry et al. 2009), tetrachloroethylene (Bois et al. 1996a; Chiu and Bois 2006; 
Covington et al. 2007), toluene (Jonsson and Johanson 2001b; Vicini et al. 1999), and 
trichloroethylene (Bois 2000). Extension to questions of optimal design (Bois et al. 1999), 
medical image analysis (Brochot et al. 2006), or exposure reconstruction (Allen et al. 2007) have 
also been proposed.  
8. CONCLUSIONS 
The state of the art on PBPK modelling of inter-individual variability has advanced to the point 
of being a mainstream commercial activity for drug development. We have shown how the 
concepts and tools now available (generic PBPK models, applicable to many substances, coupled 
to databases of parameter distributions and QSAR models; MCMC software routines for 
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Bayesian data integration) can foster predictive toxicokinetics for environmental or occupational 
contaminants. Computation time is not an issue anymore, and the approach is being extended to 
toxicodynamics through the use of biology-motivated effect models, toward a true predictive 
toxicology applicable to very large number of chemicals. 
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FIGURE CAPTIONS 
Figure 1: Structure of a generic PBPK model of the mammalian body. 
Figure 2: The inter-correlation of covariates affecting drug clearance. 
Figure 3: Blood concentrations of isopropanol (IPA) and its metabolite acetone as a function of 
age for continuous inhalation exposure at 1 ppb. 
Figure 4: Paraoxon AUC distribution for the sensitive population compared to the AUC 
distribution for the “normal” population for a parathion dose of 0.033 mg/kg. 
Figure 5: Graphical representation of a toxicokinetic population model. Unknown quantities are 
in circles, known quantities in squares. At the individual level, exposure (E), time (t) and 
specific parameters ( ) condition the data (y). The structural PBPK model, f, links E, t,  and y. 
Individual parameter values are randomly distributed in the population with population means µ 
and variances ∑2. Residual errors (measurement errors, modelling errors etc.) are lumped in the 
variance term 2. 
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FIGURES 
 
Figure 1: Structure of a generic PBPK model of the mammalian body. 
 










































Figure 2: The inter-correlation of covariates affecting a chemical’s clearance from the body, 
updated after (Jamei et al. 2009a). 




































































Figure 3: Blood concentrations of isopropanol (IPA) and its metabolite acetone as a function of 
age for continuous inhalation exposure at 1 ppb. 
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Figure 4: Paraoxon AUC distribution for the sensitive population (black bars) compared to the 
AUC distribution for the “normal” population (white bars) in for a parathion dose of 0.033 
mg/kg. 








Figure 5: Graphical representation of a toxicokinetic population model. Unknown quantities are 
in circles, known quantities in squares. At the individual level, exposure (E), time (t) and 
specific parameters ( ) condition the data (y). The structural PBPK model, f, links E, t,  and y. 
Individual parameter values are randomly distributed in the population with population means µ 
and variances ∑2. Residual errors (measurement errors, modelling errors etc.) are lumped in the 
variance term 2. 
 
